Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Idera Pharmaceuticals (IDRA)

Idera Pharmaceuticals (IDRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Idera: Q3 Earnings Snapshot

Idera: Q3 Earnings Snapshot

IDRA : 7.2250 (-21.57%)
Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results

EXTON, Pa., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported...

IDRA : 7.2250 (-21.57%)
Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC

– Enrollment Stopped Early for Efficacy –...

IDRA : 7.2250 (-21.57%)
Idera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

EXTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its...

IDRA : 7.2250 (-21.57%)
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

EXTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported...

IDRA : 7.2250 (-21.57%)
Idera Pharmaceuticals Announces Tilsotolimod Updates

EXTON, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” and “our”) (Nasdaq: IDRA) today announced...

IDRA : 7.2250 (-21.57%)
Idera: Q3 Earnings Snapshot

EXTON, Pa. (AP) _ Idera Pharmaceuticals Inc. (IDRA) on Monday reported a loss of $6 million in its third quarter.

IDRA : 7.2250 (-21.57%)
Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

EXTON, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported...

IDRA : 7.2250 (-21.57%)
Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

EXTON, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter...

IDRA : 7.2250 (-21.57%)
Idera Pharmaceuticals Announces Corporate Updates

EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today announced that it will not continue ILLUMINATE-301, the Company’s trial...

IDRA : 7.2250 (-21.57%)

Barchart Exclusives

How Surging AI Demand Could Drive This Dividend Stock Higher
Eaton, a diversified power management company, is poised to benefit from the surging demand for AI-driven data centers, with its innovative power solutions and strong dividend growth making it an attractive investment opportunity. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar